The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The data showed that both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

BioNTech said Thursday it has agreed to acquire smaller biotech CureVac in a $1.25 billion all-stock deal in another push to ...

Note that some links may require registration or subscription. An Air India passenger plane bound for London with more than ...

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Health Secretary Robert F. Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on Wednesday, ...